"10.1371_journal.pone.0131010","plos one","2015-07-24T00:00:00Z","Laura James; Ke Yan; Lisa Pence; Pippa Simpson; Sudeepa Bhattacharyya; Pritmohinder Gill; Lynda Letzig; Gregory Kearns; Richard Beger","Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR 72202, United States of America; Arkansas Children’s Hospital Research Institute, Little Rock, AR 72202, United States of America; Medical College of Wisconsin, Milwaukee, WI 53226, United States of America; Division of Systems Biology, National Center for Toxicological Research, Jefferson, AR 72079, United States of America; Division of Pediatric Pharmacology, Medical Toxicology and Therapeutic Innovation, The Children’s Mercy Hospital, Kansas City, MO 64108, United States of America","Conceived and designed the experiments: LJ RB. Performed the experiments: LP LL. Analyzed the data: PS KY SB. Contributed reagents/materials/analysis tools: SB PG. Wrote the paper: LJ SB GK PG RB.","The authors have the following interests: Dr. Laura James is part owner of Acetaminophen Toxicity Diagnostics, (ATD) LLC, which has developed a rapid assay for the measurement of acetaminophen protein adducts. ATD, LLC did not participate in the study design or analysis of the data. Laura James received partial salary support from a grant awarded to ATD, LLC from the National Institutes of Diabetes, Digestive and Kidney Disease (DK79387). ATD, LLC has a patent pending [Anti-Acetaminophen Antibodies and Acetaminophen Protein Adducts, PTO Ref No. 62/086,923]. Data management for the study was provided by KAI Research, Inc, an Altarum Company. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2015","07","Laura James","LJ",9,TRUE,2,2,3,5,TRUE,FALSE,FALSE,0,NA,FALSE
